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Abstract
Background: MicroRNA-663a expression is downregulated in several tumors. However, its functions and mechanisms
in human non-small cell lung (NSCLC) cancer remain obscure. The present study aimed to identify the expression
pattern, biological roles and potential mechanisms by which miR-663a dysregulation is associated with NSCLC.
Methods: We examined expression level of miR-663a in 62 cases of NSCLC tissues and 5 NSCLC cell lines by
reverse transcription PCR. In vitro, gain-of-function and loss-of-function experiments were performed to examine
the impact of miR-663a on proliferation, cell cycle progression and invasion of NSCLC cells. Using fluorescence
reporter assays, we also explored the potential targets and possible mechanisms of miR-663a in NSCLC cells.
Results: Downregulation of miR-663a was observed in 42 of 62 of lung cancer tissues compared with paired
normal tissues (mean cancer/normal value = 0.745) and its downregulation correlated with nodal metastasis.
Transfection of miR-663a mimic suppressed cell proliferation, cell cycle progression and invasion, with downregulation
of cyclin D1, cyclin E and MMP9 in both H460 and H1299 cell lines. Transfection of miR-663a inhibitor in both H460
and H1299 cell lines exhibited the opposite effects. In addition, we confirmed that miR-663a could inhibit AP-1 activity
and AP-1 component JunD was a direct target of miR-663a in lung cancer cells. Transfection of miR-663a
mimic downregulated JunD expression. In addition, JunD siRNA treatment abrogated miR-663a inhibitor-induced
expression of cyclin D1, cyclin E and MMP9. Above all, both miRNA mimic and inhibitor in two different NSCLC cell
lines demonstrated that miR-663a inhibits proliferation and invasion by targeting AP-1 transcription factor JunD.
Conclusions: This study indicates that miR-663a downregulation might be associated with NSCLC progression.
MiR-663a suppresses proliferation and invasion by targeting AP-1 component JunD in NSCLC cells.
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Background
Lung cancer is the leading cause of cancer-related death
worldwide, and the incidence of lung cancer is increas-
ing [1]. Overall, the 5-year survival rate has remained at
15 % for the past two decades. Although targeted
therapies have been established, genetic mutations
causing activation of these gene products are identified
only in a limited number of cancers [2, 3]. On the other
hand, a variety of complex genetic, epigenetic, and micro-
environmental factors play important roles in survival and
invasion of tumor cells [4–7]. Hence, identification of
these biological factors and elucidation of their regulatory
pathways in governing tumor development, invasion, and
metastasis is an important step toward the rational design
of drugs for treatment of advanced NSCLC.
MicroRNAs (miRNAs) are a class of small non-coding
RNAs, approximately 20–25 nucleotides, which regulate
gene expression post-transcriptionally. Nearly 50 % of
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human miRNAs are located at fragile sites and gen-
omic regions involved in cancers [8–10]. Emerging
evidence shows that miRNA dysregulation is associ-
ated with various cancers including lung cancer [10, 11].
Previous studies have shown that miR-663a, a member of
primate-specific miRNA family, is associated with a variety
of important biologic processes such as viral infection, in-
flammatory responses and autoimmune diseases [12, 13].
However, its role in tumor progression is controversial.
miR-663a serves as a potential tumor suppressor in gastric
cancer, colorectal carcinomaand acute lymphoblastic
leukemia [14–17], while it acts as an oncogene in naso-
pharyngeal carcinoma and breast cancer [18, 19].
In the present study, we evaluated miR-663a expres-
sion and clinical relevance in human non-small cell
lung cancer tissues. Its involvement in biological be-
havior and the underlying molecular mechanisms
were also investigated. Our data identified miR-663a
as a potential tumor suppressor in human lung non-
small cell lung cancer.
Methods
Samples
Fresh samples from lung cancer and corresponding nor-
mal adjacent tissue were obtained from patients at
Shengjing of China Medical University between January
2011 and November 2013 with informed consent. None
of the patients in the study received any chemotherapy
or radiation therapy before surgery. This study was con-
ducted with the approval of the Ethics Committee at
Shengjing Hospital of China Medical University. Written
informed consent was obtained from all patients. Research
carried out is in compliance with the Helsinki Declaration.
Tumor samples were stored at -80 °C for RNA extraction
(the percentage of tumor tissue was >90 %).
Cell culture, reagents and transfection
HBE135, H1299, H157, H1395, H460 and H3255 cell
lines were obtained from American Type Culture Col-
lection (Manassas, VA, USA). Cells were cultured in
RPMI-1640 (Invitrogen, Carlsbad, CA, USA) containing
10 % fetal calf serum (Invitrogen, Carlsbad, CA, USA),
100 IU/ml penicillin (Sigma, St. Louis, MO, USA), and
100 μg/ml streptomycin (Sigma). Cells were grown on
sterilized culture dishes and were passaged every 2 days
with 0.25 % trypsin (Invitrogen, Carlsbad, CA, USA).
A mimic negative control, miR-663a mimic, an in-
hibitor negative control and a miR-663a inhibitor
were purchased from RiboBio (Guangzhou, China).
miRNA mimic is small, double-stranded RNA mol-
ecule, designed to mimic endogenous mature miRNA
molecules when transfected into cells. miRNA inhibi-
tor is small, single-stranded RNA with chemical
modification that regulate gene expression by binding
to and inhibiting a specific mature miRNA. MiR-663a
mimic and inhibitor were transfected using Dharma-
fect1 Transfection Reagent (Dharmacon Lafayette,
CO, USA). Briefly, complexes containing the mimic
or inhibitor were prepared according to the manufac-
turer’s protocol and then cells were transfected with
mimic negative control (100nM), miR-663a mimic
(100nM), inhibitor control (200nM) or miR-663a in-
hibitor (200nM), respectively.
siGENOME SMARTpool siRNA for JunD and Non-
targeting siRNA #1 were purchased from Dharmacon
(100nM per well). The cells were transfected with siRNA
using the DharmaFECT 1 (0.20 μL/well; Dharmacon
Lafayette, CO, USA) according to the manufacturer’s
protocol.
Quantitative real-time PCR
Total RNA was extracted from fresh tissues and cells
using Trizol (Invitrogen, Carlsbad, CA, USA) according
to the manufacturer’s instructions. Quantitative real-
time PCR was performed using SYBR Green PCR master
mix (Applied Biosystems, Foster City, CA, USA) on
7900HT Fast Real-Time PCR System (Applied Biosys-
tems, Foster City, CA, USA). Primers for miR-663a
(Bulge-LoopTM miRNA qRT-PCR Primer Set for has-
miR-663a, RiboBio, Guangzhou, China) and U6 (U6
snRNA qRT-PCR Primer Set, RiboBio, Guangzhou,
China) were used for PCR analysis in accordance with
the manufacturer’s protocol. Other primers are as
followers: cyclin D1 forward, 5′-GCTGGAGGTCTGCG
AGGA-3′, cyclin D1 reverse, 5′-ACAGGAAGCGGTC
CAGGTAGT-3, cyclin E forward, 5′-AGCCAGCCT
TGGGACAATAAT-3′, cyclin E reverse, 5′-GAGCCT
CTGGATGGTGCAAT-3′, p21 forward, 5′-CCTCATCC
CGTGTTCTCCTTT-3′. p21 reverse, 5′-GTACCACCC
AGCGGACAAGT-3′. CDK4 forward, 5′-CCGAAGT
TCTTCTGCAGTCC-3′. CDK4 reverse, 5′-GTCGGCT
TCAGAGTTTCCAC-3′. CDK6 forward, 5′-GTGACCA
GCAGCGGACAAAT-3′. CDK6 reverse, 5′-CCACA
GCGTGACGACCACT-3′. MMP2 forward, 5′-TGTG





GTAC-3′, β-actin reverse, 5′-CACCTTCTACAATG
AGCTGCGTGTG-3′. A dissociation step was per-
formed to generate a melting curve to confirm the
specificity of the amplification. Each PCR analysis was
performed in triplicate. The relative levels of gene ex-
pression were represented as ΔCt = Ct gene –Ct refer-
ence, and the fold change of gene expression was
calculated by the 2-ΔΔCt method.
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Western blot analysis
Total proteins from cells were extracted in lysis buffer
(Pierce, Rockford, IL, USA) and quantified using the
Bradford method. 50 μg protein was separated by SDS-
PAGE. Samples were transferred to polyvinylidene fluoride
membranes (Millipore, Billerica, MA, USA) and incubated
overnight at 4 °C with antibody against cyclin D1(1:1000,
Cell Signaling Technology, Boston, MA, USA), cyclin E
(1:1000, Cell Signaling Technology, Boston, MA, USA),
p21(1:1000, Cell Signaling Technology, Boston, MA,
USA), CDK4(1:1000, Cell Signaling Technology, Boston,
MA, USA), CDK6 (1:1000, Cell Signaling Technology,
Boston, MA, USA), MMP2(1:1000, Cell Signaling Tech-
nology, Boston, MA, USA), MMP9(1:1000, Cell Signaling
Technology, Boston, MA, USA) and JunD (1:1000, Cell
Signaling Technology, Boston, MA, USA) and GAPDH
(1:1000; Santa Cruz, CA, USA). After incubation with
peroxidase-coupled anti-mouse/rabbit IgG (1:1000, Cell
Signaling Technology, Boston, MA, USA) at 37 °C for 2 h,
bound proteins were visualized using ECL (Pierce,
Rockford, IL, USA) and detected using a DNR BioI-
maging System (DNR, Jerusalem, Israel). Relative pro-
tein levels were quantified using ImageJ software.
Colony formation assay
For evaluation of colony formation, cells were transfected
for 48 h before being seeded into 6-cm cell culture dishes
(800 per dish) and incubated for 14 days. The plates were
washed with PBS and the colonies were stained with the
Giemsa dye. The number of colonies with more than 50
cells was manually counted under the microscope.
Cell cycle analysis by flow cytometry
Cells (500,000) were seeded into 6 cm tissue culture
dishes and cultured overnight. Forty eight hours after
transfection, cells were harvested, fixed in cold 70 %
ethanol washed with phosphate-buffered saline (PBS)
and stained with 5 mg/ml propidium iodide in PBS sup-
plemented with RNase A (Roche, Indianapolis, IN) for
30 min at room temperature. The cells were analyzed by
flow cytometer (Becton-Dickinson and Co., San Jose,
CA, USA). One-parameter histogram was plotted ac-
cording to the distribution of nuclear DNA content in
each cell detected by flow cytometer. Cells in each indi-
vidual phase of the cell cycle were determined based on
their DNA ploidy profile.
Matrigel invasion assay
Cell invasion assay was performed using 24-well transwell
chambers with pore size of 8 μm, and the inserts were
coated with 20 μl Matrigel (1:3 dilution, BD Bioscience,
San Jose, CA, USA). Sixty hours after transfection, cells
were trypsinized, transferred to the upper matrigel cham-
ber in 100 μl serum-free medium containing 3 × 105 cells,
and incubated for 18 h. Medium supplemented with 10 %
FBS was added to the lower chamber as the chemoattract-
ant. Then, the non-invading cells on the upper membrane
surface were removed with a cotton tip, and the cells that
passed through the filter were fixed in 4 % paraformalde-
hyde and stained with hematoxylin. The experiments were
performed in triplicate.
Luciferase reporter assay
Reporter gene transfection and luciferase activity assay
were performed as follows: cells in confluent growth on a
24 well plate were co-transfected with the firefly luciferase
reporter (0.2 μg) along with the Renilla luciferase reporter
(0.02 μg), which was used for normalization, using Attrac-
tene reagent (Qiagen, Hilden, Germany) according to the
protocols provided by the manufacturers. The reporter
plasmids of AP-1 were purchased from Biotime Biotech-
nology, China. The pAP1-Luc contains SV40 early enhan-
cer/promoter. The AP-1 response element was listed as
follows: GGCCTAACTG GCCGGTACCG CTAGCTG
ACT AATGACTAAT GACTAATGAC; CCGGATTGAC
CGGCCATGGC GATCGACTGA TTACTGATTA CT
GATTACTG. The luciferase activity was measured in cel-
lular extracts using a dual luciferase reported gene assay
kit (Promega, San Luis Obispo, CA, USA). The relative ac-
tivity of the reporter gene was calculated by dividing the
signals from firefly luciferase reporter by the signals ob-
tained from Renilla luciferase reporter.
Validation for interaction of miRNAs and Target Genes
using Luciferase Reporter Assays
A pmiR-RB-REPORT™ vector (Ribobio Co., Guangzhou,
China) was used for 3′ UTR-luciferase reporter assays to
detect interactions of miR-663a with JunD (Gene ID:
3727). The TargetScan Human database 6.2 http://tar-
getscan.org/was used to identify miRNA binding sites.
The Wild-type miR-663a target site in JunD 3′-untrans-
lated region was CCCCGCC. The mutant miR-663a
target site was CGGGCGC. The miR-663a mimic, miR-
663a inhibitor and their corresponding negative controls
(Ribobio Co. Guangzhou, China) were transfected with
pmiR-RB-REPORT™-target gene UTR. Reporter assays
were conducted in triplicate. The cells were co-
transfected with 100 nM mimic and 100 ng/mL reporter
plasmid by attractene agent (Qiagen, Hilden, Germany)
according to the manufacturer’s instructions
Statistical analysis
SPSS version 11.5 for Windows was used for all statis-
tical analyses. Student’s t-test was used to compare
densitometry data on focus numbers between control
and treated cells. All p values are based on a two-sided
statistical analysis and p < 0.05 was considered to indi-
cate statistical significance.
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Results
miR-663a expression was downregulated in NSCLC and
associated with lymph lode metastasis
We examined levels of miR-663a by RT-qPCR in 62 fresh
NSCLC tissue samples with paired normal lung tissues.
As shown in Fig. 1a, the expression levels of miR-663a
were downregulated in 42 of 62 NSCLC tissues. As shown
in the boxplot (Fig. 1b), the mean level of miR-663a was
lower in NSCLC tissues than in normal lung tissues (mean
cancer/normal value = 0.745). To determine the effect of
miR-663a on tumor progression, NSCLC patients were di-
vided into two groups, low and high expression, according
to the median relative expression level of miR-663a in
cancerous tissues (median cancer/normal value = 0.773).
Fig. 1 Low expression level of miR-663a in lung cancer patients. a Paired bar chart showing relative expression of 62 fresh NSCLC tissues and
paired normal tissues. b Boxplot indicates mean miR-663a levels in NSCLC tissues and paired normal tissues. c Bar chart showing correlation between
miR-663a expression level and TNM stage, lymph node status of 62 fresh paired samples. In stageI NSCLC, the percentage of high miR-663a expression
was 60 % and in stageII-III NSCLC, the percentage was 37.1 %. In NSCLC without nodal metastasis, the percentage of high miR-663a was 59.6 % and in
NSCLC without nodal metastasis, the percentage was 30 %. d Boxplot indicates mean cancer/normal miR-663a ratio in stageI and stageII-III
NSCLC tissues. e Boxplot indicates mean cancer/normal miR-663a ratio in NSCLC tissues with or without nodal metastasis. f Relationship between
miR-663a and JunD mRNA expression in NSCLC tissues (p = 0.005)
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Correlations between miR-663a expression and clini-
copathologic variables were shown in Table 1. Significant
correlation was observed between miR-663a expression
and nodal status (p = 0.0297) (Chi-Square test). In 20
cases presenting with positive nodal status, 14 (70.0 %)
cases had low expression of miR-663a, while the low
expression rate was 17/42 (40.4 %) in tumor samples
without nodal metastasis (Fig. 1c-e). No correlation
was observed between miR-663a expression and gender
(p = 0.7668), age (p = 0.7926), histology type (p = 0.7978),
stage (p = 0.0730) or histological grade (p = 0.3508).
miR-663a regulates cell proliferation and invasion in vitro
We examined the expression of miR-663a in normal
bronchial cell line HBE135 and 5 NSCLC cell lines:
H1299 (adenocarcinoma), H3255 (adenocarcinoma),
H460 (large cell carcinoma), H1395 (adenocarcinoma)
and H157 (squamous cell carcinoma) using RT-qPCR.
As shown in Fig. 2a, compared to the expression in
HBE135, downregulation of miR-663a was observed in
H157, H1395 and H460 cell lines. H3255 cell line has
the same level of miR-663a as HBE135 and H1299 has
relative high expression. We explored the potential ef-
fects of miR-663a on proliferation, cell cycle progres-
sion and invasion in lung cancer cells. According to
the expression of miR-663a in NSCLC cell lines, we
selected H460 cells for miR-663a mimic transfection
and H1299 cells for miR-663a inhibitor transfection.
Then we examined the efficiency of miR-663a mimic
and inhibitor by real-time PCR at 48 h after transfec-
tion. As shown in Fig. 2a, miR-663a mimic significantly
upregulated miR-663a in H460 cells and inhibitor down-
regulated miR-663a expression in H1299 cells. Colony for-
mation assay showed that colony number of H460 cells
transfected with miR-663 mimic was significantly de-
creased (control 596 ± 28 vs mimic 401 ± 18, p < 0.05),
while colony formation ability of H1299 transfected with
miR-663a inhibitor was increased (control 171 ± 16 vs in-
hibitor 295 ± 18, p < 0.05) (Fig. 2b). Cell cycle analysis
showed that treatment of miR-663a mimic inhibited G1-S
transtion, while miR-663a inhibitor treatment facilitated
cell cycle progression (Fig. 2c).
Matrigel invasion assays were also performed, and ex-
ogenously increase of miR-663a expression significantly
reduced the number of invasive cells by 41.8 % in H460
cells (control 86 ± 6 vs mimic 50 ± 3, p < 0.05) (Fig. 2d).
The number of invasive cells significantly increased by
48.8 % in H1299 cellstransfected with miR-663a inhibi-
tor compared with the control cells (control 84 ± 5 vs in-
hibitor 125 ± 9, p < 0.05) (Fig. 2d).
In addition, to demonstrate the underlying mecha-
nisms of miR-663a- mediated inhibition of proliferation
and invasion, weexamined expression of cell cycle and
invasion related proteins, including cyclin D1, cyclin E,
p21, CDK4, CDK6, MMP2 and MMP9 by realtime PCR
and western blot. The results showed that miR-663a
mimic transfection could downregulate cyclin D1, cyclin
E and MMP9 expression, while treatment with miR-663a
inhibitor upregulated these proteins (Fig. 3a and b). The
effect of miR-663a on other proteins was not obvious.
Since the difference in miR-663a levels between
H1299 and H460 cells is not large, we also transfected
miR-663a inhibitor in H460 cells and miR-663a mimic
in H1299 cells to further confirm the results. Consistent
with the above findings, we found that colony number
of H1299 cells transfected with a mimic was significantly
decreased (control 278 ± 20 vs mimic 169 ± 18, p < 0.05),
while colony formation ability of H460 transfected with
miR-663a inhibitor was increased (control 415 ± 32 vs
mimic 581 ± 19, p < 0.05). Similarly, cell cycle analysis
showed that treatment of miR-663a mimic in H1299
cells inhibited G1-S transtion, while miR-663a inhibitor
treatment in H460 cells facilitated cell cycle progression.
In addition, exogenously upregulation of miR-663a in
H1299 cells reduced the number of invasive cells signifi-
cantly (control 72 ± 3 vs mimic 46 ± 4, p < 0.05). The










< 60 23 12 11 0.7926
≥ 60 39 19 20
Gender
Male 47 24 23 0.7668
Female 15 7 8
Histology





Well 10 7 3 0.3508
Moderate 42 20 22
Poor 10 4 6
TNM stage
I 35 14 21 0.0730
II + III 27 17 10
Tumor status
T1 16 7 9 0.5616
T2 - T4 46 24 22
Nodal status
N0 42 17 25 0.0297
N1 - N3 20 14 6
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number of invasive cells in H460 cells increased signifi-
cantly when transfected with miR-663a inhibitor (control
45 ± 3 vs mimic 61 ± 4, p < 0.05). Finally, we assessed the
roles of miR-663a in the regulation of cell-cycle and cell-
invasion related molecules. As expected, miR-663a in-
hibitor increased both protein and mRNA expression of
cyclin D1, cyclin E, MMP9 and JunD in H460 cells,
meanwhile miR-663a mimic showed opposite effects in
H1299 cells (Additional file 1: Figure S1).
miR-663a inhibits AP-1 transcription activity by targeting
JunD
Since miR-663a could downregulate cyclin D1, cyclin E
and MMP9 expression, we examined several signaling
pathways which could regulate these genes simultan-
eously. Using luciferase reporter plasmid, we found that
miR-663a mimic transfection inhibited AP-1 transcrip-
tion activity and miR-663a inhibitor increased AP-1 ac-
tivity (Fig. 4a).
To determine potential target genes of miR-663a in
NSCLC, the TargetScan Human database 6.2 was used.
Among the genes in the target list, we focused on JunD
which is an AP-1 component and a key mediator of
tumor cell proliferation, metastasis and chemoresistance
in a variety of tumors (Additional file 2: Figure S2). To
evaluate whether JunD is regulated by miR-663a in vitro,
we transfected H460 cells with miR-663a mimic and de-
tected the mRNA and protein levels of JunD 48 h after
transfection.. As shown in Fig. 4, ectopic expression of
miR-663a significantly decreased both mRNA and pro-
tein expression of JunD compared to controls., indicat-
ing miR-663a as a potent regulator of JunD.
To further determine if JunD was a direct target of
miR-663a, fluorescent reporter assays were performed.
According to a previous study [15], the 3′-UTR of JunD
with wild-type (CCCCGCC) and mutant (CGGGCGC)
Fig. 2 Effects of miR-663a on proliferation and invasion in NSCLC
cells. a Expression of miR-663a in 5 NSCLC cell lines (H1299, H3255,
H460, H1395, H157) and normal bronchial cell line HBE135. miR-663a
mimic significantly upregulated miR-663a level in H460 cells and its
inhibitor downregulated miR-663a expression in H1299 cells. b
Colony number of H460 cells transfected with miR-663a mimic
was lower than cells transfected with control (control 596 ± 28 vs
mimic 401 ± 18, p < 0.001). Colony number of H1299 transfected
with miR-663a inhibitor was higher than cells transfected with
control (control 171 ± 16 vs inhibitor 295 ± 18, p < 0.001). c miR-663a
mimic increased G1 phase percentage and decreased S phase
percentage in H460 cells. miR-663a inhibitor decreased G1 phase
percentage and increased S phase percentage in H1299 cells. d
Matrigel invasion assay showed that invading number of H460
transfected with miR-663a mimic was lower than cells transfected with
control (control 86 ± 6 vs mimic 50 ± 3, p < 0.001). Invading number of
H1299 cells transfected with miR-663a inhibitor was higher than cells
transfected with control (control 84 ± 5 vs inhibitor 125 ± 9, p < 0.001).
*p < 0.05, Error bars indicate standard deviation
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binding sites for miR-663a was cloned into pmiR-RB-
REPORT vector. The ratio of fluorescence intensity for
wild-type and mutant binding sites was calculated. As
shown in Fig. 4c, miR-663a mimic reduced the fluores-
cence intensity in H460 cells transfected with a vector
containing wild-type JunD 3′-UTR compared with con-
trols, while no significant change was observed in cells
transfected with vector containing mutant binding site.
These results indicated that miR-663a binds to JunD 3′-
UTR region directly and downregulates JunD mRNA ex-
pression. To validate this, we analyzed the relationship
between miR-663a and JunD mRNA expression in
NSCLC tissues using linear regression. We found that
miR-663a negatively correlated with JunD mRNA ex-
pression (Fig. 1f, p = 0.005).
To confirm the role of JunD-AP1 axis in miR-663a in-
duced inhibition of cyclin proteins and MMP9. We
knocked down JunD using siRNA in H1299 cell line.
Western blot and realtime PCR analysis showed that
JunD depletion downregulated mRNA and protein ex-
pression of cyclin D1, cyclin E and MMP9. In addition,
in JunD siRNA treated H1299 cells, miR-663a inhibitor
failed to upregulate cyclin D1, cyclin E and MMP9.
These results indicated the pivotal role of JunD in miR-
663a mediated inhibition of cell growth and invasion.
Discussion
Accumulated evidence in the literature implicates an
important role of miR-663a in cancer development
[14–17]. It was reported that expression of miR-663a
was significantly downregulated in pediatric AML
cells, which may caused by hypermethylation of the
miR-663a promoter [17]. Downregulation of miR-663a
was also observed in gastric cancers and introduction
of miR-663a into the human gastric cancer cells sup-
pressed proliferation and mitotic catastrophe [14]. In
addition, the tumor suppressive role of miR-663a was
demonstrated in colorectal cancer cells [16], prostate
cancer and especially in glioblastoma, in which miR-
663a targeted PIK3CD and served as a prognostic
biomarker [20]. However, the involvement of miR-
Fig. 3 miR-663a regulates mRNA and protein expression of cyclin
D1, cyclin E and MMP9. a Western blot showed that cyclin D1,
cyclin E and MMP9 protein levels of H460 cells treated with miR-663a
mimic were lower than those of control. cyclin D1, cyclin E,
MMP9 protein levels of H1299 cells treated with miR-663a inhibitor
were higher than those of control. Protein quantification of protein
was shown for cyclin D1, cyclin E and MMP9 in these two cell lines.
b Realtime PCR analysis showed that cyclin D1, cyclin E, MMP9 mRNA
expression of H460 cells treated with miR-663a mimic were lower than
those of cells transfected with control. cyclin D1, cyclin E, MMP9 mRNA
expression of H1299 cells treated with miR-663a inhibitor were higher
than those of cells transfected with control. Experiments were repeated
in triplicate. Error bars indicate standard deviation
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663a in tumor progression remains controversial and
some reports implied miR-663a as a oncogene in
breast and nasopharyngeal carcinoma [18, 19]. So far,
little is known about the expression pattern of miR-
663a in NSCLC and its effects on tumor invasion and
cell cycle progression. In the present study, we found
that miR-663a was significantly downregulated in
NSCLC tissues and cell lines by RT-qPCR analysis,
which is consistent with previous reports [14, 17, 18, 20].
In addition, statistical analysis showed that miR-663a
downregulation correlated with lymph node metastasis.
The level of miR-663a was also lower in several lung can-
cer cell lines compared with normal bronchial cell line
HBE135. These results suggested that downregulation of
miR-663a might be a useful predictor of NSCLC.
The precise molecular mechanisms for the altered ex-
pression of miR-663a in lung cancers remain unknown.
It was reported hypermethylation of miR-663apromoter,
which could be affected by 5-Aza demethylation,was ob-
served in acute myeloid leukemia [17]. Thus, aberrant
epigenetic events may contribute to miR-663a dysregula-
tion in lung cancer and this needs further studies.
The biological functions of miR-663a in lung cancer
cells and the possible mechanisms were investigated.
Cell cycle analysis and colony formation assays showed
that miR-663a inhibited cell growth and induced cell
cycle arrest, and importantly,a series of cell cycle regula-
tors, including cyclin D1 and cyclin E, were affected by
miR-663a. The correlation of low miR-663a expression-
with lymph node metastasis indicated that, as a potential
tumor suppressor, miR-663a might not only regulate cell
cycle but also invasion and tumor metastasis by regulat-
ing multiple oncogenes. As expected, transwell assays
revealed that miR-663a suppressed cell invasion, and
western blot results showed that MMP9, a
Fig. 4 miR-663a targeted AP-1 component JunD in NSCLC cells. a In
H460 cells transfected with miR-663a mimic, the AP-1 activity
was lower than that in H460 cells transfected with control. The
AP-1 activity in H1299 transfected with miR-663a inhibitor was
higher than that transfected with control. b JunD protein and
mRNA expression in H460 cells treated with miR-663a mimic was
lower than that in H460 cells transfected with control. JunD protein
and mRNA expression in H1299 treated with miR-663a inhibitor was
higher than that in H1299 cells transfected with control. c Wild-
type and mutant miR-663a binding sites in the 3′-UTR of JunD
were assessed using fluorescent reporter assays. The fluorescence
activity of miR-663a mimic/mimic control was calculated. In H460
cells transfected with reporter vector containing wild-type binding site,
the luciferase activity in cells with miR-663a mimic was lower than that
in control cells. d JunD siRNA treatment in H1299 cells downregulated
protein and mRNA expression of cyclin D1, cyclin E and MMP9. In JunD
depleted cells, difference of cyclin D1, cyclin E, MMP9 mRNA in
cells treated with control and miR-663a inhibitor was not signifi-
cant. Experiments were repeated in triplicate. *p < 0.05, Error bars
indicate standard deviation
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criticalinvasion regulator, was downregulated after in-
duction of miR-663a mimic and upregulated with miR-
663a inhibitor treatment. These results suggested that
miR-663a suppresses cell growth and invasion through
inhibition of Cyclins and MMP9 expression.
AP-1 signaling was reported to regulate cyclin D1,
cyclin E and MMP9 in various cancers including NSCLC
[7, 21]. Using luciferase reporter plasmid, we found that
miR-663a inhibited AP-1 transcription activity. So
among the potential miR-663a targets list predicted by
TargetScan Human database, we sparked a strong inter-
ested in JunD which is a functional component of the
AP1 transcription factor complex and also a proved tar-
get of miR-663a in human THP-1 monocytic cell [15].
In vitro overexpression of miR-663a significantly de-
creased JunD mRNA and protein expression compared
to controls, whereas inhibition of miR-663a led to in-
creased JunD mRNA and protein. Correspondingly, we
also found a negative correlation between miR-663a and
JunD mRNA in NSCLC tissues. Furthermore, fluores-
cent reporter assays demonstrated that miR-663a dir-
ectly bound to the JunD 3′-UTR region, which was in
accordance with previous report [15]. As an AP-1 tran-
scription factor, JunD was reported to accelerate growth,
inhibit apoptosis and enhance cancer cell invasion
[22–26]. Using siRNA knockdown, we confirmed that
JunD downregulation decreased expression of cyclin
D1, cyclin E and MMP9 in lung cancer cells. JunD
siRNA also abrogated the effect of miR-663a inhibitor.
Thus our results indicated that miR-663a inhibited
cell cycle and invasion, at least partly, through regula-
tion of JunD expression.
Conclusions
In conclusion, miR-663a, a downregulated miRNA in
NSCLC, was associated with lymph node metastasis. In
addition, miR-663a regulated cell cycle and invasion by tar-
geting AP-1 component JunD, which provides new insights
into the molecular mechanisms of lung cancer progression.
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278 ± 20 vs inhibitor 169 ± 18, p < 0.001). B. Matrigel invasion assay showed
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72 ± 3 vs inhibitor 46 ± 4, p < 0.001). C. Western blot showed that cyclin D1,
cyclin E, MMP9, JunD protein levels of H460 cells treated with miR-663a in-
hibitor were higher than those of control. cyclin D1, cyclin E, MMP9, JunD
protein levels of H1299 cells treated with miR-663a mimic were lower than
those of control. D. Realtime RT-PCR showed that cyclin D1, cyclin E, MMP9,
JunD mRNA levels of H460 cells treated with miR-663a inhibitor were higher
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